Multiple sclerosis and drugs of ingredients of ipratropium bromide (a real world drug study)
Summary:
Multiple sclerosis is found among people who take drugs with ingredients of ipratropium bromide, especially for people who are female, 60+ old , have been taking the drugs for 2 - 5 years. This phase IV clinical study is created by eHealthMe based on reports of 62,375 people who have side effects when taking drugs with ingredients of ipratropium bromide from the FDA, and is updated regularly.
Drug(s) considered in the study (i.e. both brand name and generic drugs): Atrovent, Atrovent hfa, Ipratropium bromide.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
62,375 people reported to have side effects when taking drugs with ingredients of ipratropium bromide.
Among them, 131 people (0.21%) have Multiple sclerosis
What is Multiple sclerosis?
Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,085 drugs and 1,365 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.
Number of reports submitted per year:
Time on drugs with ingredients of ipratropium bromide when people have Multiple sclerosis *:
- < 1 month: 0.0 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 100 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Multiple sclerosis when taking drugs with ingredients of ipratropium bromide *:
- female: 83.72 %
- male: 16.28 %
Age of people who have Multiple sclerosis when taking drugs with ingredients of ipratropium bromide *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 1.08 %
- 20-29: 1.08 %
- 30-39: 4.3 %
- 40-49: 30.11 %
- 50-59: 26.88 %
- 60+: 36.56 %
Conditions people have *:
You may use this to check any potential undetected conditions.
Other drugs people take *:
You may use this to check any potential interacting drugs.
Other side effects people have besides Multiple sclerosis *:
You may use this to check any potential undetected side effects.
* Approximation only. Some reports may have incomplete information.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Related studies
Drugs with ingredients of ipratropium bromide, their effectiveness, alternatives and more:
How the study uses the data?
The study uses data from the FDA. It is based on ipratropium bromide. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Agitation and Mental Status Changes - 2 seconds ago
- Methotrexate and Oxycodone drug interactions for boys aged 2-9 - 2 seconds ago
- Nasonex and Magnesium drug interactions for men aged 50-59 - 4 seconds ago
- Haemolytic Uraemic Syndrome and Hair Loss - 4 seconds ago
- Ibuprofen and Pegintron drug interactions for men aged 50-59 - 4 seconds ago
- Methotrexate and Oxycodone drug interactions for girls aged 2-9 - 5 seconds ago
- Nexium and Hepatic Coma for Men aged 60+ - 7 seconds ago
- Nexium and Encephalopathy - Hepatic for Men aged 60+ - 7 seconds ago
- Vasculitis and drugs of ingredients of diclofenac sodium - 7 seconds ago
- Duodenal Polyp and drugs of ingredients of rivaroxaban - 7 seconds ago